FANGZHOU JIANKE (06086) surged over 8% in afternoon trading. As of press time, the stock was up 6.34% to HK$4.36, with turnover reaching HK$35.3192 million.

On the news front, FANGZHOU JIANKE previously released its interim results showing revenue of 1.494 billion yuan for the first half of the year, representing a 12.9% year-on-year increase. Net profit turned from loss to profit, reaching 12.5 million yuan, while adjusted net profit hit a new high of 17.6 million yuan, up 16.8% year-on-year. The company achieved significant progress in its core businesses.

Specifically, online retail pharmacy services revenue reached 864 million yuan, surging 28.2% year-on-year, while comprehensive medical services business revenue came in at 357 million yuan, up 11.4% year-on-year.

Notably, FANGZHOU JIANKE recently signed a strategic cooperation memorandum with global leading biopharmaceutical company Novo-Nordisk A/S. As a leading AI + internet healthcare company, FANGZHOU JIANKE will leverage its smart healthcare ecosystem and robust technology foundation to build a comprehensive health management service loop covering medication guidance, medication reminders, effectiveness tracking, and health education. This aims to create a new ecosystem value chain in the diabetes and weight management sector, fully promoting the transition from "disease-centered" to "health-centered" approaches for diabetes and obesity, providing patients with higher quality and more convenient one-stop services.